MedTrace Logo

NAD Supplementation and Vascular Health in PAD

NCT06534944 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2026-04-06

No results posted yet for this study

Summary

This pilot open-label clinical trial was designed to investigate whether 4-week supplementation with 1g daily NR impacts endothelial function in peripheral circulation, cerebrovascular hemodynamics, cognitive function in older adults with peripheral artery disease.

Conditions

Interventions

DRUG

Nicotinamide riboside

NR 1g daily for 4 weeks

Sponsors & Collaborators

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • Andriy Yabluchanskiy, MD, PhD · University of Oklahoma

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-27
Primary Completion
2024-07-30
Completion
2024-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06534944 on ClinicalTrials.gov